Limits...
Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.

Chung KH, Kim W, Kim BG, Lee HY, Jin E, Cho Y, Seo JY, Kim HY, Jung YJ, Kim JW, Jeong JB, Lee KL - Gut Liver (2015)

Bottom Line: Serum HBsAg titers and paired HBV DNA concentrations in the different phases of CHB were compared using 627 serum samples.Mean HBsAg titers were significantly higher in the immunotolerant (IT) phase and immunoreactive (IR) HBeAg-positive phase than in the low-replicative (LR) and HBeAg-negative CHB (ENH) states.The correlation between HBsAg titers and HBV DNA concentrations was modest in the IT (n=36, r=0.804, p<0.001) and IR (n=48, r=0.773, p<0.001) phases, and it was poor in the LR state (n=116, r=0.289, p=0.002); however, no significant correlation was observed in the ENH state (n=67, r=0.146, p=0.237) or in the oral nucleos(t)ide analogue-treated group (n=267).

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Quantification of hepatitis B surface antigen (HBsAg) is an emerging serologic test and may be useful for identifying treatment strategies for chronic hepatitis B (CHB). This study aimed to evaluate HBsAg titers during the natural course of CHB and identify correlations between HBsAg titers and hepatitis B virus (HBV) DNA concentrations across different CHB phases measured using an immunoradiometric assay (IRMA).

Methods: CHB phases were defined on the basis of HBV DNA concentrations, the presence of hepatitis B e antigen/antibody (HBeAg/Ab) and serum alanine aminotransferase levels. Serum HBsAg titers and paired HBV DNA concentrations in the different phases of CHB were compared using 627 serum samples.

Results: Mean HBsAg titers were significantly higher in the immunotolerant (IT) phase and immunoreactive (IR) HBeAg-positive phase than in the low-replicative (LR) and HBeAg-negative CHB (ENH) states. The correlation between HBsAg titers and HBV DNA concentrations was modest in the IT (n=36, r=0.804, p<0.001) and IR (n=48, r=0.773, p<0.001) phases, and it was poor in the LR state (n=116, r=0.289, p=0.002); however, no significant correlation was observed in the ENH state (n=67, r=0.146, p=0.237) or in the oral nucleos(t)ide analogue-treated group (n=267).

Conclusions: HBsAg quantification using IRMA might be useful for discriminating different CHB phases and different stages of chronic liver disease.

No MeSH data available.


Related in: MedlinePlus

Comparison of mean hepatitis B surface antigen (HBsAg) titers among the different phases of chronic hepatitis B (CHB) and the different treatment outcome groups. (A) Treatment-naive patients; (B) nucleos(t)ide-treated patients.IT, immunotolerant phase; IR, immunoreactive hepatitis B e antigen (HBeAg)-positive phase; LR, low-replicative phase; ENH, HBeAg-negative CHB; E+VR, HBeAg-positive CHB with virologic response; E+pVR, HBeAg-positive CHB with partial virologic response; E-VR, HBeAg-negative CHB with virologic response; E-pVR, HBeAg-negative CHB with partial virologic response.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562784&req=5

f1-gnl-09-657: Comparison of mean hepatitis B surface antigen (HBsAg) titers among the different phases of chronic hepatitis B (CHB) and the different treatment outcome groups. (A) Treatment-naive patients; (B) nucleos(t)ide-treated patients.IT, immunotolerant phase; IR, immunoreactive hepatitis B e antigen (HBeAg)-positive phase; LR, low-replicative phase; ENH, HBeAg-negative CHB; E+VR, HBeAg-positive CHB with virologic response; E+pVR, HBeAg-positive CHB with partial virologic response; E-VR, HBeAg-negative CHB with virologic response; E-pVR, HBeAg-negative CHB with partial virologic response.

Mentions: The mean HBsAg titers significantly differed among eight subgroups, and the titer values per phase for the treatment-naive patients averaged 71,686.7 IU/mL in IT, 36,995.5 IU/mL in IR, 7,317.0 IU/mL in LR, and 7,805.4 IU/mL in ENH (Fig. 1A). The mean HBsAg titer was significantly higher in IT than in IR (p=0.043) but, the difference in the mean HBsAg titers between LR and ENH was not statistically significant (p=0.121). The mean HBsAg titers per phase for the NUC-treated patients were 8,273.5 IU/mL in E+VR, 13,368.8 IU/mL in E+pVR, 3,751.6 IU/mL in E-VR, and 5,172.8 IU/mL in E-pVR (Fig. 1B). The mean HBsAg titer was significantly higher in E+pVR than in E+VR (p=0.027), and was also significantly higher in E-pVR than in E-VR (p=0.009) The mean HBsAg titer was significantly higher in IT plus IR than in LR plus ENH (p<0.001), and was significantly higher in the HBeAg-positive group than in the HBeAg-negative group, irrespective of the use of NUCs (p<0.001).


Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.

Chung KH, Kim W, Kim BG, Lee HY, Jin E, Cho Y, Seo JY, Kim HY, Jung YJ, Kim JW, Jeong JB, Lee KL - Gut Liver (2015)

Comparison of mean hepatitis B surface antigen (HBsAg) titers among the different phases of chronic hepatitis B (CHB) and the different treatment outcome groups. (A) Treatment-naive patients; (B) nucleos(t)ide-treated patients.IT, immunotolerant phase; IR, immunoreactive hepatitis B e antigen (HBeAg)-positive phase; LR, low-replicative phase; ENH, HBeAg-negative CHB; E+VR, HBeAg-positive CHB with virologic response; E+pVR, HBeAg-positive CHB with partial virologic response; E-VR, HBeAg-negative CHB with virologic response; E-pVR, HBeAg-negative CHB with partial virologic response.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562784&req=5

f1-gnl-09-657: Comparison of mean hepatitis B surface antigen (HBsAg) titers among the different phases of chronic hepatitis B (CHB) and the different treatment outcome groups. (A) Treatment-naive patients; (B) nucleos(t)ide-treated patients.IT, immunotolerant phase; IR, immunoreactive hepatitis B e antigen (HBeAg)-positive phase; LR, low-replicative phase; ENH, HBeAg-negative CHB; E+VR, HBeAg-positive CHB with virologic response; E+pVR, HBeAg-positive CHB with partial virologic response; E-VR, HBeAg-negative CHB with virologic response; E-pVR, HBeAg-negative CHB with partial virologic response.
Mentions: The mean HBsAg titers significantly differed among eight subgroups, and the titer values per phase for the treatment-naive patients averaged 71,686.7 IU/mL in IT, 36,995.5 IU/mL in IR, 7,317.0 IU/mL in LR, and 7,805.4 IU/mL in ENH (Fig. 1A). The mean HBsAg titer was significantly higher in IT than in IR (p=0.043) but, the difference in the mean HBsAg titers between LR and ENH was not statistically significant (p=0.121). The mean HBsAg titers per phase for the NUC-treated patients were 8,273.5 IU/mL in E+VR, 13,368.8 IU/mL in E+pVR, 3,751.6 IU/mL in E-VR, and 5,172.8 IU/mL in E-pVR (Fig. 1B). The mean HBsAg titer was significantly higher in E+pVR than in E+VR (p=0.027), and was also significantly higher in E-pVR than in E-VR (p=0.009) The mean HBsAg titer was significantly higher in IT plus IR than in LR plus ENH (p<0.001), and was significantly higher in the HBeAg-positive group than in the HBeAg-negative group, irrespective of the use of NUCs (p<0.001).

Bottom Line: Serum HBsAg titers and paired HBV DNA concentrations in the different phases of CHB were compared using 627 serum samples.Mean HBsAg titers were significantly higher in the immunotolerant (IT) phase and immunoreactive (IR) HBeAg-positive phase than in the low-replicative (LR) and HBeAg-negative CHB (ENH) states.The correlation between HBsAg titers and HBV DNA concentrations was modest in the IT (n=36, r=0.804, p<0.001) and IR (n=48, r=0.773, p<0.001) phases, and it was poor in the LR state (n=116, r=0.289, p=0.002); however, no significant correlation was observed in the ENH state (n=67, r=0.146, p=0.237) or in the oral nucleos(t)ide analogue-treated group (n=267).

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Quantification of hepatitis B surface antigen (HBsAg) is an emerging serologic test and may be useful for identifying treatment strategies for chronic hepatitis B (CHB). This study aimed to evaluate HBsAg titers during the natural course of CHB and identify correlations between HBsAg titers and hepatitis B virus (HBV) DNA concentrations across different CHB phases measured using an immunoradiometric assay (IRMA).

Methods: CHB phases were defined on the basis of HBV DNA concentrations, the presence of hepatitis B e antigen/antibody (HBeAg/Ab) and serum alanine aminotransferase levels. Serum HBsAg titers and paired HBV DNA concentrations in the different phases of CHB were compared using 627 serum samples.

Results: Mean HBsAg titers were significantly higher in the immunotolerant (IT) phase and immunoreactive (IR) HBeAg-positive phase than in the low-replicative (LR) and HBeAg-negative CHB (ENH) states. The correlation between HBsAg titers and HBV DNA concentrations was modest in the IT (n=36, r=0.804, p<0.001) and IR (n=48, r=0.773, p<0.001) phases, and it was poor in the LR state (n=116, r=0.289, p=0.002); however, no significant correlation was observed in the ENH state (n=67, r=0.146, p=0.237) or in the oral nucleos(t)ide analogue-treated group (n=267).

Conclusions: HBsAg quantification using IRMA might be useful for discriminating different CHB phases and different stages of chronic liver disease.

No MeSH data available.


Related in: MedlinePlus